The Venture Codex

Participated · Seed · Jul 2024

Biostate AI develops generative AI models that predict the evolution of human disease and drug response using RNA sequencing data. The company combines software models with patented wetlab technologies, including its BIRT platform, to enable affordable, scalable collection of large transcriptomic and genomic datasets. It partners with hospitals, academic researchers, and biotech/pharma companies to source data and apply its models. Biostate AI operates sites in Houston, TX; Palo Alto, CA; Bangalore, India; and Shanghai, China. Founded by David Zhang and Ashwin Gopinath, the company plans to use new funding to expand operations and increase R&D efforts. Biostate AI builds a scalable biodata foundry centered on Total RNA sequencing using patent-pending Barcode-Integrated Reverse Transcription (BIRT) technology to analyze all RNA types, including lncRNAs, miRNAs, circRNAs, and eRNAs. The company also offers OmicsWeb Copilot, a conversational AI that leverages large-language models to help biologists analyze and visualize data, produce custom software and scripts, and access over 1,000 unique RNAseq datasets plus users' uploaded data. Biostate AI collaborates with academic, nonprofit, and industry partners on technology development and multiomic biodata collection. The startup plans to use its new funding to expand operations and accelerate development efforts. Led by CEO David Zhang and founded in 2023, Biostate AI maintains offices and laboratories in Palo Alto, CA and Houston, TX. The company positions itself to lower the costs of biological data collection for academic and industry collaborators.